Results 111 to 120 of about 54,010 (241)

Pancreatic Cancer—Advances in the Last 50 Years

open access: yes
World Journal of Surgery, EarlyView.
S. George Barreto   +5 more
wiley   +1 more source

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

open access: yesInternational Journal of Cancer, Volume 159, Issue 4, Page 936-950, 15 August 2026.
What's new? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar   +16 more
wiley   +1 more source

Irinotecan in combination with new agents

open access: yes, 2004
Today, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard first-line treatment for patients with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with
JL Van Laethem   +16 more
core   +1 more source

Can Response Outcomes Predict Survival in Paediatric Patients Receiving Treatment for Relapsed and Refractory Rhabdomyosarcoma? Results From the Living‐REFoRMS Systematic Review

open access: yesInternational Journal of Cancer, Volume 159, Issue 4, Page 997-1004, 15 August 2026.
Although existing research suggests a limited relationship between survival outcomes and radiological response rates in children with newly diagnosed rhabdomyosarcoma, there is little evidence in the relapsed/refractory setting. Using aggregate data collected from the Living‐REFoRMS dataset of early‐phase trials, the authors established that ...
Preethi Muthukumar   +4 more
wiley   +1 more source

Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Peritoneal metastases (PM) are common in patients with colorectal cancer. Patients with PM have a poor prognosis, and for those who are not eligible for cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC ...
Pascale C. S. Rietveld   +9 more
doaj   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

open access: yesPediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman   +7 more
wiley   +1 more source

Supplementary Material for: Irinotecan-Induced Dysarthria

open access: yes, 2017
Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second ...
van der Vliet H.J. (4131472)   +4 more
core   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

open access: yesPediatric Blood &Cancer, Volume 73, Issue 8, August 2026.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook   +6 more
wiley   +1 more source

Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

open access: yesFrontiers in Oncology
IntroductionThe aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal ...
Haeseong Park   +8 more
doaj   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

open access: yesInternational Journal of Cancer, Volume 159, Issue 3, Page 719-728, 1 August 2026.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy